The effectiveness of minimally invasive monitoring using such tools as Dexcom G7 (Dexcom Inc., California, USA), Guardian Real-Time (Medtronic MiniMed, US), and FreeStyle Libre (Abbott Diabetes Care, USA) has been confirmed in a number of clinical studies in patients with DM1, including high-risk individuals, and DM2, with insulin injections and insulin pump therapy, and in children and older adults, and during pregnancy. This evidence concerns the gene INS and diabetes mellitus.